The review highlights recent advances in our understanding of the interactions between genetic polymorphisms in genes that metabolize choline and the dietary requirements of choline and how these interactions relate to human health and disease.
INTRODUCTION
Many diseases have both genetic and environmental risk factors, and there is expanding interest in identifying interactions between dietary factors and genetic polymorphisms that alter either nutrient requirements or susceptibility to disease. This renewed interest in diet has been partially prompted by improved -omics technologies used to identify metabolites and genetic variants. The interest in environmental effects, such as diet, on disease has been in part driven by the surprisingly low heritability uncovered by current genome-wide association studies (GWAS). There is now an appreciation that the identification of how food (and other environmental factors) interacts with genetic polymorphisms may be critical to improve health. Clearly, we are moving beyond a 'one-size fits all' mentality and ultimately a better understanding of gene by diet interactions may help to refine our current dietary recommendations.
Of particular interest is the nutrient choline which is found in nuts, dairy, and meat products and was first classified as an essential nutrient based on its role in the prevention of nonalcoholic fatty liver disease (NAFLD) [1] . An individual's response to choline-deficient diets is varied and perhaps an indication of complex genetic regulation of choline requirements [2] . Additionally, the requirements for choline may vary across an individual's lifetime as maternal choline deficiency is associated with certain birth defects [3] which need to be balanced with the recent evidence that choline-derived metabolites increase cardiovascular disease (CVD) risk [4] [5] [6] .
The liver is a primary site of choline metabolism where several metabolic pathways regulate maintenance of cell membranes. For cardiovascular risk, phosphatidylcholine synthesis in the liver is also important for the assembly of VLDL particles that are responsible for transporting fat and cholesterol from the liver to peripheral organs. Thus, one effect of choline deficiency is NAFLD, and this may be a direct result of reduced levels of hepatic phosphatidylcholine leading to hepatic accumulation of fat and cholesterol. Genetic polymorphisms in genes regulating choline metabolism have been extensively studied as they have been hypothesized to modify requirements for choline. These are outlined in Figure 1 and described in detail below.
GENETIC POLYMORPHISM, DIETARY CHOLINE, AND PREGNANCY OUTCOMES
Much of the interest in choline as an essential nutrient is because of previous reports of low choline being associated with certain birth defects [7] [8] [9] . In addition to choline intake, there has been substantial interest in either the mother's genotype or fetal genotype influencing fetal choline requirements or metabolism. The premise is that identifying mothers with altered choline need or metabolism may reduce negative outcomes.
Certain polymorphisms may be particularly deleterious in the presence of dietary choline deficiencies [10, 11] . For example, polymorphisms
KEY POINTS
Insufficient intake of dietary choline in pregnant women is associated with developmental disorders.
Certain populations are more susceptible to cholinerelated diseases because of the low availability of dietary choline and the presence of polymorphisms that alter dietary choline requirements.
Choline is a methyl donor, and choline deficiency has been shown to alter global methylation patterns.
Understanding how common polymorphisms influence dietary choline requirements may allow for a more personalized approach to dietary recommendations. can transport choline into the mitochondria for further processing. In the gut, choline is the precursor of trimethylamine which is absorbed and transported to the liver for oxidation by FMO3 to TMAO. Choline is the precursor of betaine, which serves as a source of methyl groups for homocysteine remethylation to dimethylglycine and methionine. Alternatively, homocysteine can be remethylated with methyl groups from 5-methyltetrahydrofolate, which is derived from 5,10-methylenetetrahydrofolate. MTHFD1, is catalyzes the production of 5,10-methylenetetrahydrofolate from 5,10-methenyltetrahydrofolate. FMO3, flavinmonooxygenase 3; MTHFD1, methylenetetrahydrofolate dehydrogenase 1; TMAO, trimethylamine N-oxide.
in the gene methylenetetrahydrofolate dehydrogenase 1 (MTHFD1), specifically the A allele of MTHFD1 G1958A, may affect homocysteine methylation when folate availability is low [12, 13] . Thus, polymorphisms of MTHFD1 have been associated with various congenital abnormalities such as neural tube defects (NTDs) [14] , Down's syndrome, cleft lip, cleft palate [15] , and congenital heart defects. There is some heterogeneity in these data as studies have inconsistently reported the association of specific effect alleles (or underlying polymorphisms), so additional work is necessary to clarify the risk variants and their effect size. More recently, meta-analyses have identified associations between MTHFD1 polymorphisms, such as the MTHFD1 G1958A variant, as being associated with increased risk for birth defects [16] [17] [18] . Additionally, two missense mutations, rs7946 and rs897453, in PEMT, an enzyme required for de novo production of choline, have been associated with altered homocysteine levels and NTDs, respectively [19, 20] .
However, data directly linking NTDs and maternal choline levels and specific polymorphisms are inconsistent. Recently, Mills et al. conducted a study to investigate the link between NTDs and maternal choline levels and associated Single Nucleotide Polymorphisms (SNPs). They measured choline and betaine levels and looked at SNPs in the phosphatidylethanolamine N-methyltransferase (PEMT) gene in women with a current NTD-affected pregnancy, women with a previous NTD-affected pregnancy currently pregnant and unaffected, and unaffected control women. They reported that the levels of choline and betaine did not differ in women who had a current NTD-affected pregnancy. Cases were significantly more likely to have the G allele of PEMT rs7946 (V175 M, þ5465 G.A) [15] . It is quite possible that these polymorphisms affect fetal or maternal choline requirements, but it was not possible to measure umbilical cord metabolite levels in this particular study. Another group recently compared maternal plasma levels of choline, betaine, dimethylglycine, and trimethylamine Noxide (TMAO) in pregnant women at 16 weeks of gestation, at delivery, and in umbilical cord plasma [21 && ]. Mean maternal plasma-free choline, dimethylglycine, and TMAO concentrations increased during pregnancy by 49, 17, and 13%, respectively, whereas betaine concentrations decreased by 21%. Curiously, cord plasma concentrations of free choline and betaine were 3.2 and 2.0 times higher than maternal plasma values at delivery, indicating perhaps an altered requirement for these metabolites by the fetus. The authors did not find an association between maternal diet, as assessed by a food frequency questionnaire, and cord plasma concentrations of choline, nor did they find any associations between fetal genotype of 10 candidate SNPs and cord plasma concentrations of choline. Improving our understanding of how maternal dietary requirements and genetics interact to affect fetal health has important public health implications.
EPIGENETIC EFFECTS
An area of intense interest is the effect of maternal diet on offspring because of altered epigenetic marks that control gene expression [22] . Choline is particularly interesting as it is a methyl donor, and thus differences in choline status could affect global DNA methylation. Studies in rodents have found that the gestational availability of choline has a large impact on DNA methylation and researchers are focusing on understanding how these specific changes in methylation may affect disease risk. A study using a toxic milk mouse model of Wilson's disease on a C3H/HeJ background found that maternal choline supplementation altered transcript levels of methionine and lipid metabolism genes. In this study, maternal choline supplementation increased global DNA methylation measured in fetal livers, indicating the importance of dietary choline during fetal development [23] . Additional studies have argued that the availability of methyl donors is tightly regulated, and that high levels of methylation are not universally protective as increased DNA methylation may be linked to behavioral disorders [24] [25] [26] .
Understanding the effects of choline and 1-carbon metabolites on the human epigenome is an area of active investigation. Interestingly, although not surprisingly, the effects of choline deficiency have been identified as population specific, likely because of differences in gene allele frequency in certain populations as well as dietary differences among populations. In a recent study focused on women in rural Gambia, researchers showed that seasonal variations in methyl-donor nutrient intake in mothers as early as conception influenced maternal plasma concentrations of several key methyl-donor pathway substrates, including choline, betaine, methionine, and homocysteine, which in turn were shown to influence the methylation status of fetal alleles [27] .
GENETIC POLYMORPHISM, DIETARY CHOLINE, AND METABOLIC DISEASE
Initial interest in choline metabolites and CVD arose via the association between homocysteine levels and CVD, but this association is now considered inconclusive [28] . To better understand these data, recent research has focused on specific polymorphisms that alter homocysteine levels such as those in MTHFR, the enzyme that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is a substrate required for conversion of homocysteine to methionine. The SNP rs1801133 has been linked to elevated plasma homocysteine levels and increased risk of coronary artery disease (CAD) [29] ; however, the mechanisms by which elevated homocysteine levels promote CAD are still not well understood, and other studies have failed to replicate this result [30] . Studies in different ethnicities have identified a similar association between A1298C and CVD in two independent Indian populations [31, 32] . A meta-analysis of 6912 individuals confirmed that the C677T polymorphism is also associated with premature CAD [33] . It is not clear from these studies if different choline intake (dietary substrate) is the source of these disparate results. It is important to note that some of the heterogeneity in the literature may in fact be because of dramatic differences in folate levels supplied in the diet. In 1997, folate supplementation was mandated, and thus it is possible that certain results are discordant because of this difference in substrate availability for these enzymatic reactions.
More importantly, a recent randomized clinical trial to evaluate the efficacy of folic acid therapy in the prevention of strokes grouped participants based on MTHFR C677T genotype. This study found that folic acid therapy significantly reduced stroke risk among participants with the CC or CT genotypes, but not among those with the TT genotype [34] , and these results may extend to renal disease [35] . The association of MTHFR is complicated as SNPs, including rs13306561, rs1801133, and rs17367504, in the gene have been associated with increases in DBP, but these associations have not been replicated across studies [36, 37] . There is a possibility that some of the effects of these polymorphisms mediate expression of MTHFR from the recent identification of a polymorphism at the locus that affects its expression. This variant has also been associated with CVD-related traits [38] .
There is evidence that genetic variations in the PEMT gene also affect choline metabolism. Polymorphisms such as the variant tagged by the C allele of rs12325817 in PEMT were found to be associated with development of organ dysfunction in individuals fed a choline-deficient diet [2] . Furthermore, previous results have shown an interesting interaction of PEMT and estrogen signaling. For this reason, of particular interest are two potential functional variants: an amino acid substitution, Val58-Leu (rs897453), in a transmembrane domain of PEMT and rs750546, which is found in the ESR1 binding site of PEMT [39] . The specific effect of these polymorphisms on CVD risk remains unknown, but the importance of PEMT in CVD was shown by recent studies in genetically modified mice [40] . For example, Pemt À/À mice have reduced circulating homocysteine levels and resistance to atherosclerotic lesions, signifying the importance of PEMT in CVD [41] . Pemt À/À mice also exhibit low-plasma VLDL levels and develop fatty livers in response to a high-fat diet, which was partially ameliorated when the diets were supplemented with choline as hepatic cholesterol levels decreased and liver function improved. These data suggest that genetic variants of PEMT alter dietary choline requirements and that choline requirements could vary by an individual's genotype.
THE GUT MICROBIOME REGULATES CHOLINE LEVELS AND CONTRIBUTES TO COMPLEX DISEASES IN HUMANS
For several years, researchers have studied the role of the gut microbiome in complex diseases such as cancer, obesity, diabetes, CVD, and NAFLD [42] [43] [44] [45] . Direct links have been made between these various diseases and the regulation of choline levels, especially in situations of dietary choline deficiency [46] . TMAO, a derivative of choline, was identified as a predictive biomarker linking the microbiome and CVD risk [47, 48] . TMAO is an oxidation product of trimethylamine (TMA) that is found in both humans and mice. TMAO is synthesized as a conversion product from TMA, which is derived from the breakdown of dietary choline-containing compounds by the gut microbiota.
There are widespread differences in the microbiota composition among humans that could affect the metabolism and bioavailability of dietary choline. For example, Romano et al. identified several isolates, from a collection of 79 sequenced human intestinal samples, capable of producing TMA from choline in vitro. They identified nine bacterial strains capable of producing TMA from choline in vitro and tested these using gnotobiotic mice to show that TMAO accumulates in the serum of animals colonized with TMA-producing species. Remarkably, low levels of colonization by TMA-producing bacteria significantly reduced choline levels available to the host which was more pronounced as the abundance of TMA-producing bacteria increased in the gnotobiotic mice [49 && ]. These important studies indicate that the composition of the microbiome affects plasma TMAO and choline concentrations. These results are particularly intriguing given studies that have shown that egg consumption leads to increased TMAO concentrations in the blood [47] . This result was confirmed in a small clinical study that demonstrated that 11-15% of dietary total choline is converted into TMAO after consumption of a meal that contained eggs [6] .
Normally, TMA is oxidized to TMAO primarily through the action of flavin mono-oxygenase 3 (FMO3). Studies in mice have shown a direct link between plasma levels of TMAO, FMO3 expression, and atherosclerosis [5] . More recent studies have identified FMO3 as a key metabolic gene that affects lipid and glucose metabolism. Studies in LDLr À/ À mice treated with antisense FMO3 oligonucleotides exhibited decreases in hepatic lipids and in levels of plasma lipids, ketone bodies, glucose, and insulin, whereas opposite effects were observed with transgenic mice overexpressing FMO3 [50] . Knockdown of FMO3 in cholesterol-fed mice alters biliary lipid secretion, blunts intestinal cholesterol absorption, and limits the production of hepatic oxysterols and cholesteryl esters. Furthermore, FMO3 knockdown stimulates basal and liver X receptor-stimulated macrophage reverse cholesterol transport, thereby improving cholesterol balance [51] .
NOVEL REGULATORY VARIANTS AND CHOLINE STATUS
Identification of genetic variants affecting choline requirements could be used to refine our dietary recommendations in pregnancy and in cardiovascular patients. A targeted genetic study of 200 SNPs in 10 candidate genes selected for their biochemical importance in choline metabolism identified novel associations with liver and muscle function in study participants fed a low-choline diet [52 && ]. The authors used a combination of clinical studies in which patients were fed a choline-deficient diet while under medical supervision and were deemed to have organ dysfunction when they developed increased creatine phosphokinase or aspartate aminotransferase levels. Genotypes were then compared between patients with organ dysfunction and patients that were resistant to choline restriction. Novel SNPs in SLC44A1, CHKA, and CHKB were identified as associated with increased choline requirements, and there was an indication that some of the SNPs in SLC44A1 may differentiate between patients who develop muscle dysfunction or hepatic dysfunction. The authors then tested the allele frequency of these SNPs in Mexican Americans, European Americans, Asian-Americans, and Africans (n ¼ 100/population) and several of the SNPs associated with choline requirements in the clinical study were dramatically different between these small population cohorts. For example, rs7873937, a SNP in SLC44A1, was present in all populations except Asian-Americans. They concluded that these differences in allele frequency could alter the choline requirement in a population-specific manner [52 && ]. These data are supported by a case report of a patient with postural orthostatic tachycardia syndrome. This patient had decreased levels of the choline transporter SLC44A1 and reduced plasma choline levels, suggesting an intriguing link between SLC44A1 and plasma choline [53] . These data suggest that genetic variants of choline metabolizing enzymes can alter dietary choline requirements and that choline requirements could vary by an individual's genotype.
The identification of SNPs in key genes regulating choline metabolism as associated with human diseases across multiple general populations and among small isolated populations indicates the importance of this pathway in regulating multiple complex processes contributing to human health. Dietary choline intake varies geographically and different populations exhibit different allele frequencies in key choline metabolism genes. For this reason, a recently published study sought to identify whether key SNPs that increase dependence on dietary choline would be under selective pressure specifically in a geographic location with a prevalent choline-poor diet [10] . They assessed CHDH rs12676, MTHFD1 rs2236225, and PEMT rs12325817 for negative selective pressure in The Gambia, West Africa, known for its cholinedeficient diet, versus two other populations with choline-rich diets, including a genetically similar population in East Africa and a genetically dissimilar population in the USA. The authors used two different genetic models to demonstrate minor allele frequencies of polymorphisms associated with increased choline requirements between the Gambian and the other populations. Although difficult to definitively test in this particular study, the authors hypothesize that the dramatic difference in allele frequency is actually driven by historical dietary differences between these populations. These data do present the intriguing question of whether our genetically programmed needs for specific nutrients may in fact be partially determined by ethnicity and/or selective pressures because of historical diets of our ancestors.
In addition to genes that may affect the metabolism of choline, recent studies have been focused on determining the genetics underlying the association of TMAO with CVD as this metabolite is a byproduct of microbial metabolism of choline. Based on the highly variable plasma TMAO levels observed in human studies, it is reasonable to hypothesize that TMAO levels are affected by the intrinsic genetic factors of the host. However, with the exception of FMO3, deficiency of which leads to elevated TMA and decreased TMAO levels [5] , the genes that control plasma TMAO levels are not known. A comparative GWAS approach using a large mouse genetic reference population and $2000 study participants was used to identify candidate genes [4] . These studies identified a genome-wide significant locus on chromosome 3 associated with plasma TMAO concentrations in mice on a chow diet (P ¼ 2.37 Â 10 À6 ). This locus also exhibited highly significant evidence (P ¼ 1.07 Â 10 À20 ) for cis-regulation of solute carrier family 30 member 7 (Slc30a7) expression in the liver. The colocalization of loci for plasma TMAO and Slc30a7 mRNA levels suggest that this zinc transporter represents a positional candidate gene responsible for the association signal at this locus. By comparison, no locus exceeding the genome-wide significance threshold was observed in the human GWAS, including the orthologous region on human chromosome 1p21.2 harboring SLC30A7 or at the FMO3 locus, which indicates the complex genetic regulation of TMAO concentrations. Supporting these findings, a GWAS in the Framingham Heart Study also failed to detect significant associations for plasma TMAO concentrations, although several suggestively associated loci were also identified [54] . Further GWAS investigations that account for differences in choline or l-carnitine intake may better identify genes regulating plasma levels of TMAO.
CONCLUSION
We are just beginning to understand the complex interactions between diet and genetic polymorphisms. Here we discuss choline as it has been shown to be a clinically important nutrient that has been associated with diseases of deficiency in the case of birth defects, whereas excessively elevated choline levels are associated with CVD risk. Polymorphisms in several candidate genes demonstrate that genetic perturbations can affect the metabolism of choline and presumptively an individual's dietary requirement for choline. Studies with rural African populations have demonstrated altered methylation status and indicated unique selective pressures on genes regulating choline metabolism. Studies in mice and humans with CVD indicate that gut microbial metabolism, and perhaps genetic polymorphisms of the host, influence the conversion of dietary choline into the proatherogenic metabolite TMAO. Clearly, additional work to identify the underlying genetic variants and how they relate to dietary choline requirements across a lifetime are necessary before altering our current recommendations.
